SG/CALL/MODERNA/170/0.1/17.01.25 | Delayed Deutsche Boerse AG 01:08:36 11/05/2024 am IST | ||
| 0.69 EUR | -20.69% |
|
| Current month | +29.85% | ||
| 1 month | +20.83% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/24/11 | 0.69 | -20.69% | 0 |
| 09/24/09 | 0.87 | +6.10% | 0 |
| 08/24/08 | 0.82 | +2.50% | 0 |
| 07/24/07 | 0.8 | -4.76% | 0 |
| 06/24/06 | 0.84 | -11.58% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 11, 2024 at 01:08 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SQ860T |
| ISIN | DE000SQ860T8 |
| Date issued | 16/02/2023 |
| Strike | 170 $ |
| Maturity | 17/01/2025 (252 Days) |
| Parity | 10 : 1 |
| Emission price | 5.55 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.72 € |
|---|---|
| Lowest since issue | 0.25 € |
| Spread | 0.01 € |
| Spread % | 1.43% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
122.7
USD
Average target price
139.4
USD
Spread / Average Target
+13.58%
- Stock Market
- Warrants
- Warrant